Centers | ||
|
|
|
EU-OPENSCREEN | VMCC, University of Michigan | Edinburgh Drug Discovery |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The VMCC is an on-campus core facility for the design and synthesis of drug-like molecules and diagnostic probes used in biomedical investigations. Our Mission: To assist biomedical researchers in translating novel therapeutic hypotheses into... |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
Merck Serono and Feinstein Institute to Develop New Drugs to Treat LupusMerck Serono and Feinstein Institute the research arm of North Shore-Long Island Jewish Health System in New York have entered into a joint collaboration to develop new antibody based therapies to treat Systemic Lupus Erythematosus (SLE). Merck... View all GSK and MD Anderson to co-develop new cancer therapeuticsGlaxoSmithkline and MD Anderson Cancer Center entered into a co-development and license agreement to develop antibody based therapeutics to treat cancer. Under this agreement MD Anderson grants exclusive rights to antibodies developed during the... View all Merck Establishes New Center in San Diego with Academic ResearchersMerck Pharmaceuticals has committed to fund $90 million over period of seven years to establish California Institute for Biomedical Research (Calibr) in San Diego, California. The new center will be led by Peter Schulz from the Scripps Research... View all |
No EVENTS for listing |
No Job Posts |
